Lutetium (177Lu) rhPSMA-10.1 injection
Metastatic castration-resistant prostate cancer (mCRPC)
pharma · Chronic Hepatitis D Infection · Chronic Hepatitis Delta Infection
Blue Earth Diagnostics Ireland Ltd
Blue Earth Diagnostics trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Registry index of 11 ClinicalTrials.gov studies linked to Blue Earth Diagnostics programs — each row shows trial ID, program name, phase, status, and indication.
Blue Earth Diagnostics trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Latest clinical program signals indexed for Blue Earth Diagnostics.
BS-03 — Phase 1
BS-02 — Phase 1
BET-PSMA-001 — Phase 1
Lutetium (177Lu) rhPSMA-10.1 injection — Phase 2
Placebo, BFB759 — Phase 2
BFB759, Placebo — Phase 2
[68Ga]BED003 injection — Phase 2
BJT-778 — Phase 3
Metastatic castration-resistant prostate cancer (mCRPC)
PSMA-positive non-curative metastatic castration-resistant prostate cancer
Treatment of human papilloma virus (HPV) associated infections, precancers and cancers
Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).